Medtronic plc (MDT) recently announced late-breaking data from the global Lead Evaluation for Defibrillation and Reliability (“LEADR”) Pivotal trial at Heart Rhythm 2024. The outcome showed that the investigational OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals.The trial findings were simultaneously published in the Heart Rhythm journal. The development is likely to boost Medtronic’s Cardiac Rhythm Management business within the C ...